ACAD Acadia Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ACAD

Price (delayed)

$25.97

Market cap

$4.45B

P/E Ratio

11.65

Dividend/share

N/A

EPS

$2.23

Enterprise value

$4.2B

?
Relative Growth: Rel. Growth: 53
Relative Strength: Rel. Strength: 58
Relative Valuation: Rel. Valuation: 76
Relative Profitability: Rel. Profitability: 92

Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who ...

Highlights
The company's equity has surged by 63% YoY
The debt has decreased by 13% YoY and by 3.8% QoQ
The net income has surged by 64% year-on-year but it has declined by 3.9% since the previous quarter
The EPS has soared by 62% YoY but it has decreased by 3.9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.acadia-pharm.com
Peers: VNDA PFE JNJ BMY

Key stats

What are the main financial stats of ACAD

ACAD stock price

How has the Acadia Pharmaceuticals stock price performed over time
Intraday
3.06%
1 week
9.49%
1 month
24.32%
1 year
22.27%
YTD
-2.77%
QTD
2.65%

Financial performance

How have Acadia Pharmaceuticals's revenue and profit performed over time
Revenue
$1.1B
Gross profit
$1B
Operating income
$80.91M
Net income
$375.65M
Gross margin
91.5%
Net margin
34.3%
The operating margin has shrunk by 69% YoY and by 24% QoQ
The operating income has plunged by 66% YoY and by 23% from the previous quarter
The net income has surged by 64% year-on-year but it has declined by 3.9% since the previous quarter
The net margin has increased by 49% YoY but it has decreased by 6% QoQ

Price vs fundamentals

How does ACAD's price correlate with its fundamentals

Growth

What is Acadia Pharmaceuticals's growth rate over time

Valuation

What is Acadia Pharmaceuticals stock price valuation
ACAD P/E details
P/E
11.65
P/B
3.55
P/S
4.04
EV/EBIT
36.45
EV/EBITDA
33.06
EV/Sales
3.83
The EPS has soared by 62% YoY but it has decreased by 3.9% QoQ
The stock's price to earnings (P/E) is 9% less than its last 4 quarters average of 12.8
The company's equity has surged by 63% YoY
ACAD's price to book (P/B) is 42% lower than its 5-year quarterly average of 6.1 and 7% lower than its last 4 quarters average of 3.8
ACAD's P/S is 16% below its 5-year quarterly average of 4.8 but 9% above its last 4 quarters average of 3.7
ACAD's revenue is up by 10% YoY and by 2.2% QoQ

Efficiency

How efficient is Acadia Pharmaceuticals business performance
ACAD's return on invested capital has dropped by 77% year-on-year and by 28% since the previous quarter
The ROS has shrunk by 61% YoY and by 19% QoQ
Acadia Pharmaceuticals's return on assets has increased by 21% YoY but it has decreased by 12% QoQ
The ROE has contracted by 15% from the previous quarter

Dividends

What is ACAD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACAD.

Financial health

How did Acadia Pharmaceuticals financials performed over time
The total assets has grown by 42% YoY and by 2.6% from the previous quarter
The current ratio has grown by 25% YoY but it has contracted by 6% from the previous quarter
The debt is 97% lower than the equity
The company's equity has surged by 63% YoY
The debt to equity has dropped by 50% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.